Latest Epilepsy Care News

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Epiminder Limited has achieved a major milestone with the first US implant of its Minder System at the University of Pennsylvania, kicking off a pivotal trial that could redefine epilepsy monitoring.